|
J Biol Chem, Vol. 273, Issue 28, 17610-17617, July 10, 1998
Adenosine Deaminase and A1 Adenosine Receptors
Internalize Together following Agonist-induced Receptor
Desensitization*
Carlos A.
Saura,
Josefa
Mallol,
Enric I.
Canela,
Carmen
Lluis, and
Rafael
Franco
From the Departament de Bioquímica i Biologia Molecular,
Facultat de Química, Universitat de Barcelona,
08028 Barcelona, Catalunya, Spain
 |
ABSTRACT |
A1 adenosine receptors
(A1Rs) and adenosine deaminase (ADA; EC 3.5.4.4) interact
on the cell surface of DDT1MF-2 smooth muscle cells. The
interaction facilitates ligand binding and signaling via
A1R, but it is not known whether it has a role in
homologous desensitization of A1Rs. Here we show that
chronic exposure of DDT1MF-2 cells to the A1R
agonist,
N6-(R)-(phenylisopropyl)adenosine
(R-PIA), caused a rapid aggregation or clustering of
A1 receptor molecules on the cell membrane, which was
enhanced by pretreatment with ADA. Colocalization between A1R and ADA occurred in the R-PIA-induced
clusters. Interestingly, colocalization between A1R and ADA
also occurred in intracellular vesicles after internalization of both
protein molecules in response to R-PIA. Agonist-induced
aggregation of A1Rs was mediated by phosphorylation of
A1Rs, which was enhanced and accelerated in the presence of
ADA. Ligand-induced second-messenger desensitization of
A1Rs was also accelerated in the presence of exogenous ADA, and it correlated well with receptor phosphorylation. However, although
phosphorylation of A1R returned to its basal state within minutes, desensitization continued for hours. The loss of cell-surface binding sites (sequestration) induced by the agonist was
time-dependent (t1/2= 10 ± 1 h) and was accelerated by ADA. All of these results strongly suggest
that ADA plays a key role in the regulation of A1Rs by
accelerating ligand-induced desensitization and internalization and
provide evidence that the two cell surface proteins internalize via the
same endocytic pathway.
 |
INTRODUCTION |
Adenosine is an autacoid that exerts its physiological
actions through specific cell surface receptors. Four adenosine
receptors (A1, A2A, A2B, and
A3), belonging to the family of G protein-coupled receptors, have been cloned and pharmacologically characterized (1).
Acting through different adenosine receptors, adenosine is a
neuromodulator in both the central and peripheral nervous systems (2,
3). Via A1 adenosine receptors
(A1Rs),1
adenosine reduces heart rate (4), glomerular filtration rate, and renin
release in the kidney (5); it induces bronchoconstriction (6, 7) and
inhibits lipolysis. A1Rs can be coupled to different pertussis toxin-sensitive G proteins (8-10), which mediate inhibition of adenylate cyclase (11) and regulate Ca2+ and
K+ channels and inositol phosphate metabolism (1).
A1R displays two different affinities for agonist, which
have classically been attributed to a different coupling to
heterotrimeric G proteins (12). According to this two-independent site
model, coupled receptor-G protein complexes display high affinity for
agonists (Kd = 0.1-0.2 nM), and
uncoupled receptors display low affinity (1-2 nM) (12,
13). The recently reported cluster-arranged cooperative model predicts
that the high and low affinity sites are a consequence of the negative
cooperativity of agonist binding and do not seem to be related to the
content of free and G protein-coupled receptors (14). According to the
cluster-arranged cooperative model, the agonist-induced conversion of
the high to the low affinity state may partially explain the
ligand-induced desensitization of A1R (14, 15).
Receptors belonging to the G protein-coupled receptor family are
desensitized and down-regulated in response to agonist stimulation. 2-Adrenergic receptors ( 2-ARs) constitute
the best characterized system within the G protein-coupled receptor
family. Agonist-induced 2-AR desensitization is caused
by a conformational change of the agonist-occupied receptor that
facilitates receptor phosphorylation by second messenger-activated
kinases or G protein-coupled receptor kinases (16, 17). Following
2-AR phosphorylation, -arrestin binds to the
phosphorylated receptor and uncouples the receptor from the
heterotrimeric G proteins (18, 19). -Arrestin not only desensitizes
the receptor but also functions as a clathrin adaptor, mediating
receptor sequestration, i.e. receptor internalization toward
intracellular compartments (20, 21). Although sequestration is not
required for phosphorylation and desensitization, it appears to be
necessary for dephosphorylation and resensitization of
2-ARs (22, 23).
Like other G protein-coupled receptor members, A1R
expression is regulated in response to agonist or antagonist
stimulation. Desensitization of A1R has been described in
intact animals and in cell cultures. Prolonged administration of
A1R agonists to animals leads to functional desensitization
of A1R in guinea pig heart (24), rat adipocytes (25), rat
atrial muscle (26), and rat brain (27, 28). The reduced functional
response is due to a net loss of A1Rs or down-regulation, a
decrease in the proportion of A1R displaying the high
affinity state for agonists and a decrease in the content of
Gi proteins. Growth of rat adipocytes or smooth muscle
DDT1MF-2 cells in the presence of
N6-(R)-(phenylisopropyl)adenosine
(R-PIA) leads to the desensitization and down-regulation of
A1R (29) along with Gi -subunits (30, 31).
We have recently shown that treatment of DDT1MF-2 cells with the agonist R-PIA induces a rapid phosphorylation and
clustering of A1Rs. The loss of binding sites on the cell
membrane due to internalization of A1R is a slower event
occurring within hours. Since activators of protein kinase A or C
mimicked the effect of the ligand, Ser/Thr phosphorylation seems to be
related to short term clustering and desensitization as well as to long
term internalization of A1R (32).
A new perspective on the coupling of A1R to G proteins has
recently been provided. Ecto-adenosine deaminase (ecto-ADA; EC 3.5.4.4), which is capable of degrading adenosine to inosine on the
cell surface (for a review, see Ref. 33), was shown to modulate ligand
binding and signaling through A1Rs on DDT1MF-2 cells (34). Irrespective of its catalytic activity, ADA seems to be
necessary for a high affinity binding of agonists to A1R (35).
Here the effect of ADA on the ligand-mediated regulation of
A1R in DDT1MF-2 cells has been studied. ADA
affected both desensitization and internalization of A1Rs.
Moreover, by means of immunocytochemistry, confocal microscopy, and
flow cytometry using antibodies against A1R and ADA, we
found that A1R and ADA colocalize and that, after receptor
activation, they cluster on the cell surface and internalize via the
same pathway. All of these results provide evidence for concerted
modulation of ADA and A1R in response to receptor
agonists.
 |
EXPERIMENTAL PROCEDURES |
Materials--
[Adenine-2,8-3H,ethyl-2-3H]phenylisopropyladenosine
([3H]R-PIA) (36 Ci/mmol) was obtained
from Amersham Pharmacia Biotech (Nuclear Iberica, Madrid, Spain).
[32P]orthophosphate (32Pi) was
from NEN Life Science Products. 1,3-Dipropyl-8-cyclopentylxanthine was
from Research Biochemicals (Natick, MA). R-PIA, pepstatin, leupeptin, chymostatin, antipain, phenylmethylsulfonyl fluoride, Fura-2/AM, fluorescein isothiocyanate, rhodamine isothiocyanate, and
calf adenosine deaminase (ADA) were purchased from Sigma. ADA was
desalted with a Sephadex G-25 column (Amersham Pharmacia Biotech) prior
to all assays. A unit of enzyme activity corresponds to 130 nmol of ADA
protein. Electrophoresis reagents were obtained from Boehringer
Manheim. Sephadex G-25 and protein A-Sepharose CL4B were from Pharmacia
LKB Biotechnology (Uppsala, Sweden). All other products were obtained
from Merck.
Antibodies and Fluorescent Probes--
Antisera against purified
calf ADA and against peptides of A1 adenosine receptor
(PC10 and PC20) were generated by immunization of female New Zealand
White rabbits by the Biokit Company (Barcelona, Spain). Antibodies
against A1Rs (PC11 and PC21) were purified from serum by
affinity chromatography (peptide coupled to thiol-Sepharose 4B
(Amersham Pharmacia Biotech)). Anti-ADA antibody was purified using ADA
coupled to cyanogen bromide-activated Sepharose (Amersham Pharmacia
Biotech). The specificity of antibodies for their respective antigens
and extensive characterization of anti-ADA and anti-A1R antibodies (PC11 and PC21) have been previously reported (36, 37). PC11
and PC21 antibodies do not recognize ADA from DDT1MF-2 cell
extracts by immunoblotting, immunoprecipitation, or immunocytochemistry (34). PC21 and PC11 A1R antibodies were shown to be
specific for cells expressing A1Rs (32).
Fluorescence probes were obtained by reacting (for 2 h at
20 °C) 0.1 mg of fluorescein or rhodamine isothiocyanate with 1 mg
of purified protein in coupling buffer (50 mM
H3BO3, 200 mM NaCl, pH 9.2).
Unbound fluorochrome was removed by rapid filtration through a Sephadex
G-25 column (Amersham Pharmacia Biotech), and fractions were tested for
protein content. Aliquots were stored at 80 °C.
Cell Cultures and Protein
Determination--
DDT1MF-2 smooth muscle cells derived
from a steroid-induced leiomyosarcoma of Syrian hamster vas deferens
were obtained from the American Type Culture Collection. Cells were
cultured (at 37 °C, 5% CO2) in Dulbecco's modified
Eagle's medium (DMEM) (Whittaker, Walkersville, NY), 1% nonessential
amino acids, 2 mM L-glutamine, 1 mM
sodium pyruvate, 5% (v/v) horse serum, and 5% (v/v) fetal calf serum
(Life Technologies, Inc.). Desensitization and internalization assays
were performed with cells growing in the absence or in the presence of
65 nM ADA and/or 50 nM R-PIA. At the
indicated incubation times, cells were harvested and washed
exhaustively in cold phosphate-buffered saline (PBS) before binding,
immunocytochemistry, and intracellular calcium mobilization assays.
Protein content was measured by the BCA method (Pierce), as described
by Sorensen and Brodbeck (38).
Radioligand Binding Assays--
For binding assays, untreated or
treated DDT1MF-2 cells (1 mg/ml) were resuspended in
serum-free DMEM buffered with 20 mM HEPES, pH 7.4, and
preincubated with 65 nM ADA for 30 min at 4 °C. Radioligand binding was performed in the presence of 5 nM
of [3H]R-PIA for 4 h at 4 °C.
Nonspecific binding was performed in the presence of a 400-fold excess
of R-PIA. Nonspecific binding with a 500-fold excess of the
selective A1R antagonist 1,3-dipropyl-8-cyclopentylxanthine resulted in similar displacement of [3H]R-PIA
binding. When equilibrium had been reached, incubates were filtered
through glass fiber filters (GF/C filters, Whatman, Kent, United
Kingdom) in a Brandel cell harvester (Biomedical Research and
Development Laboratories, Gaithersburg, MD). Filters were washed in 5 ml of ice-cold PBS and transferred to vials containing 10 ml of
scintillation solution EcoscintH (National Diagnostics, Atlanta, GA).
After overnight shaking, vials were counted using a Packard 1600 TRI-CARB scintillation counter with 50% efficiency. All points
represent the mean of 3-5 independent experiments performed in
triplicate.
Phosphorylation Assays--
A1R phosphorylation was
induced by 65 nM ADA and/or 50 nM
R-PIA treatment after the cellular ATP pool had been labeled
with [32P]orthophosphate. Briefly, DDT1MF-2
cells washed twice and resuspended in phosphate-free DMEM (buffered
with 20 mM HEPES, pH 7.4) were incubated (106
cells/ml, 37 °C, 2 h) with 0.1 mCi/ml
[32P]orthophosphate. Loaded cells were resuspended
(1 × 106 cells/ml) in serum-free DMEM and incubated
with the indicated reagents at 37 °C. After the corresponding
incubation times, cells were centrifuged (10 s, 14,000 rpm) in a
microcentrifuge and washed twice in 1 ml of ice-cold PBS before
disruption and solubilization (1 h at 4 °C) in 0.5 ml of lysis
buffer (20 mM HEPES, pH 7.4; 1% (v/v) Nonidet P-40; 100 mM NaCl; 1 mM Na3 VO4;
50 mM NaF; 1 mM phenylmethylsulfonyl fluoride;
10 µg/ml leupeptin, pepstatin, chymostatin, and antipain). The
solubilized preparation (0.2 mg/ml) was immediately processed for
immunoprecipitation with the anti-A1R antibody (PC11, 50 µg/ml) and protein A-Sepharose beads. Immunoprecipitated material was
washed four times in lysis buffer (1 × 1%, 2 × 0.1%, and
1 × 0% Nonidet P-40) before resuspension in 50 µl of SDS
sample buffer. SDS-polyacrylamide gel electrophoresis and
autoradiography were performed as described elsewhere (37).
Phosphorylated bands were quantified with a computing densitometer
(Molecular Dynamics, Inc.).
Immunostaining and Immunofluorescence Assays--
For
immunofluorescence staining, treated and untreated cells were washed in
PBS and fixed in 4% paraformaldehyde in PBS, pH 7.4, for 15 min at
room temperature. After two washes in PBS containing 20 mM
glycine (buffer A) and in buffer A containing 1% bovine serum albumin
(buffer B), cells were incubated with the rhodamine-conjugated anti-A1R antibody (PC21-TRITC, 75 µg/ml) and the
fluorescein-conjugated anti-ADA antibody (anti-ADA-FITC, 75 µg/ml)
or, alternatively, with the fluorescein-conjugated anti-A1R
antibody (PC21-FITC, 75 µg/ml) for 1 h at 37 °C. Three washes
in buffer B were performed before mounting the samples in
immunofluorescence medium (ICN Biomedical Inc., Costa Mesa, CA).
Internalization was analyzed by immunocytochemistry and confocal
microscopy. To follow dynamic internalization, unfixed cells growing on
glass coverslips were incubated (37 °C, 20 min) with 65 nM bovine serum albumin-FITC, with PC21-FITC (10 µg/ml),
and with 65 nM ADA-FITC and/or PC21-TRITC (10 µg/ml) and
then treated with 50 nM R-PIA at 37 °C for
24-72 h. Cells were washed twice in PBS, fixed in 4% paraformaldehyde
in PBS for 15 min, and again washed twice in PBS 20 mM
glycine. Glass coverslips were mounted as described above. Cells were
examined with a LEICA TCS confocal scanning laser microscope attached
to an inverted Leitz DMIRBE microscope (Leica Lasertechnik GmbH,
Heidelberg). Images shown are representative of at least three
experiments.
Internalization measurements for A1Rs and cell surface ADA
(ecto-ADA) were performed by immunostaining and flow cytometry analysis. Cells were grown in complete medium in the absence or presence of 50 nM R-PIA for 0-48 h. In some
experiments, ADA (65 nM) was prebound by incubation for
2 h at 4 °C; unbound enzyme was eliminated by washing twice in
PBS. Cells were fixed using 4% paraformaldehyde in PBS for 15 min at
room temperature. Cells were washed in buffer A and buffer B for 20 min
before staining with anti-ADA-FITC (75 µg/ml) or PC21-FITC (75 µg/ml). Three washes in buffer B were performed before analyzing the
mean fluorescence intensity from 5000-10,000 cells on an EPICS Profile
flow cytometer (Coulter, Hieleah, FL). Similar assays were performed
for cells incubated (30 min to 48 h at 37 °C) with 65 nM fluorescein-conjugated ADA (ADA-FITC) in the absence or
presence of 50 nM R-PIA. In order to remove as
much of the cell surface-bound ADA as possible, cells were washed once
in PBS and once in PBS/HCl, pH 2, for 15 min according to the method of
Yang et al. (39). Cells were fixed and processed for flow
cytometry as described above. For establishing comparisons in
internalization studies, the mean of fluorescence intensity taken as
reference was that found in cells incubated with 65 nM
ADA-FITC for 15 min at 37 °C. This fluorescence intensity was
similar to that found in cells incubated with 65 nM
ADA-FITC at 4 °C for 2 h, which was considered as the
background signal. Higher intensities would reflect internalization of
ADA-FITC.
Measurement of Intracellular Free Calcium--
Cells were washed
and resuspended (5 × 106 cells/ml) in Hanks'
balanced salt solution (HBSS containing 1.2 mM
CaCl2 and 20 mM HEPES, pH 7.4) and loaded with
5 µM Fura-2/AM for 30 min at 25 °C. Cells were washed
twice and resuspended in HBSS (1 × 106 cells/ml) for
20 min at room temperature. Cells were placed in a cuvette
(106 cells/2 ml of HBSS, 25 nM ADA), and
calcium peak induction was achieved by treatment with 50 nM
R-PIA at 30 °C. For short term desensitization assays
(1-15 min), cells were loaded and washed before resuspension in
prewarmed (37 °C) serum-free DMEM (1 × 106
cells/ml) and incubated with the indicated reagents. Cells were washed
three times in HBSS buffer to remove reagents before resuspension in
the same buffer and R-PIA induction of calcium mobilization as indicated above. After these three washes [Ca2+]
base-line levels were similar irrespective of the type of pretreatment. Therefore, differences in calcium mobilization were not a consequence of different calcium base-line levels in response to pretreatments. For
long term desensitization (12, 24, and 48 h), incubations were
performed before loading with Fura-2/AM. Calcium concentration was
determined in a dual wavelength Shimadzu RF-5000
spectrofluorophotometer by using the ratio of excitation wavelengths
334/366 nm with emission cut-off at 500 nm. Free calcium concentration
was calculated as described previously (40).
Statistical Analysis--
Time course curves were fitted to a
single-phase exponential decay equation, in the case of
[3H]R-PIA binding. Statistical comparisons
were made using the two-tailed Student's t test.
Differences were considered significant when p was
<0.05.
 |
RESULTS |
Effect of ADA on Cell Surface Distribution of A1Rs in
the Absence and in the Presence of Agonist--
A1
adenosine receptor (A1R) distribution on the surface of
DDT1MF-2 cells was examined by immunocytochemistry and
confocal analysis. Untreated and R-PIA-treated cells were
fixed, incubated with fluorescein-conjugated rabbit
anti-A1R antibody (PC21-FITC), and analyzed by confocal
microscopy. The PC21 antibody is directed against the second
extracellular loop of A1R and its specificity for cell
surface-expressed A1R has been previously demonstrated (32). Receptor distribution in untreated cells revealed homogenous bright staining on the surface of DDT1MF-2 cells (Fig.
1A). No major differences in
receptor distribution were observed in the presence of exogenous ADA
(65 nM) for 15 min (Fig. 1B). A 5-min exposure
of cells to the A1R agonist R-PIA (50 nM) induced the appearance of bright accumulations of
antigen on the plasma membrane, suggesting aggregation or clustering of
receptor molecules (Fig. 1C). Clustering of A1Rs
was more evident after 15 min of R-PIA exposure, when
brighter clusters were found (Fig. 1, compare C and
E). Incubation of DDT1MF-2 cells with ADA and
R-PIA changed the pattern of cell surface A1R
distribution dramatically. In the presence of ADA, clusters of
A1R were already evident at 2 min, and the label was found
as intense bright punctate accumulations at 5 or 15 min of
R-PIA treatment (Fig. 1, D and F).
This clearly shows the involvement of ecto-ADA in the regulation of the
R-PIA-induced aggregation of cell surface A1R
molecules. All images shown in Fig. 1 represent reconstructions of
multiple sections at different levels. When middle sections were
analyzed, only the cell surface staining was observed, thus ruling out
intracellular staining (data not shown; see Ref. 32).

View larger version (63K):
[in this window]
[in a new window]
|
Fig. 1.
Cell surface A1R redistribution
in response to ADA and/or R-PIA. DDT1MF-2
cells were untreated (A) or treated with 65 nM
ADA (B), 50 nM R-PIA (C
and E), or 65 nM ADA plus 50 nM
R-PIA (D and F) for 5 (C
and D) or 15 min (A, B, E,
and F) at 37 °C. Cells were fixed, processed for
immunofluorescence staining with the use of a fluorescein-conjugated
anti-A1R antibody (PC21-FITC, 75 µg/ml), and observed by
confocal microscopy. The images shown correspond to reconstructions of
several horizontal sections of representative cells. Scale
bar, 10 µm.
|
|
To analyze the codistribution of A1R and ADA on the plasma
membrane of DDT1MF-2 cells, ADA-treated cells were
incubated with or without 50 nM R-PIA for 15 min. Cells were fixed, washed, and stained by double immunofluorescence
using the fluorescein-conjugated anti-ADA antibody (anti-ADA-FITC) and
the rhodamine-conjugated anti-A1R antibody (PC21-TRITC).
Homogenous distribution of ADA and A1R on the cell surface
was observed in untreated cells (Fig. 2,
top). Superimposition of images by confocal analysis showed extensive colocalization (yellow) of both proteins on the
plasma membrane. When cells were treated (15 min) with
R-PIA, a redistribution of ADA and A1Rs, which
is consistent with clustering, was observed. R-PIA induced
aggregation of both proteins in clusters seen as punctate accumulations
of fluorescence and where colocalization between A1R and
ecto-ADA was very high (Fig. 2, bottom).

View larger version (118K):
[in this window]
[in a new window]
|
Fig. 2.
Colocalization between A1R and
ADA on the cell surface. Cells were treated with 65 nM
ADA in the absence (top) or presence (bottom) of
50 nM R-PIA for 15 min at 37 °C. After
treatment, cells were washed, fixed, and processed for
immunostaining as described under "Experimental Procedures."
Staining was performed with the fluorescein-conjugated anti-ADA
antibody (anti-ADA-FITC, 75 µg/ml) and the rhodamine-conjugated
anti-A1R antibody (PC21-TRITC, 75 µg/ml). Cells
were analyzed by double immunofluorescence with a confocal microscope
to detect ADA (green images) and A1R
(red images). Superimposition of images reveals
ADA/A1R colocalization in yellow.
Scale bar, 10 µm.
|
|
ADA Affects Ligand-induced Phosphorylation of
A1Rs--
In a previous study, we have shown that
ligand-induced phosphorylation of A1R correlates with the
clustering of receptors on the DDT1MF-2 cell surface (32).
To determine whether the potentiation of the clustering by ADA could
involve changes in receptor phosphorylation, we immunoprecipitated the
receptor from cells metabolically labeled with
[32P]orthophosphate. Exogenous ADA by itself had only a
slight effect on A1R phosphorylation. R-PIA (50 nM) induced, in the absence of ADA, a steady increase of
A1R phosphorylation from basal levels to a 2.1-fold
increase at 15 min. Interestingly, in the presence of exogenous ADA (65 nM), R-PIA induced a rapid increase in
A1R phosphorylation with a maximum rise (3-fold increase)
after 1 min; thereafter (5 and 15 min), the level of phosphorylation
declined (Fig. 3). In the presence of
ADA, receptor phosphorylation diminished to basal level after 15-30
min, whereas for cells treated with R-PIA in the absence of
the enzyme the return to basal levels of phosphorylation was
slower.

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 3.
Agonist-induced phosphorylation of
A1R in the absence or presence of ADA.
DDT1MF-2 cells were metabolically labeled with
32Pi and stimulated by means of vehicle
(control), 65 nM ADA, and/or 50 nM
R-PIA for 1 (white bars), 5 (gray bars), or 15 min (black
bars) at 37 °C. A1R were immunoprecipitated
and resolved by SDS-polyacrylamide gel electrophoresis. Gels were
autoradiographed as described under "Experimental Procedures," and
bands of phosphorylated A1R were quantified with a
computing densitometer (Molecular Dinamics). Data are expressed as
percentages of the basal level found in control cells. Data are
mean ± S.E. of four separate experiments performed in duplicate.
*, p < 0.05; **, p < 0.005 with
respect to the corresponding control at 1, 5, or 15 min. The
electrophoretic band (36 kDa) corresponding to the A1R in a
representative experiment is shown at the bottom.
|
|
Agonist-induced Desensitization of A1Rs in the Presence
of ADA--
Activation of A1Rs with adenosine or analogs
leads to both Ins(1,4,5)P3 formation and intracellular
calcium mobilization in DDT1MF-2 cells (41, 42). To
correlate changes in agonist-induced A1R phosphorylation
with possible changes in second messenger production, we analyzed the
effect of ADA and/or R-PIA on agonist-induced mobilization
of intracellular calcium. Cells were exposed to vehicle (control) or to
65 nM ADA and/or 50 nM R-PIA. After
extensive washes, calcium mobilization was induced by 50 nM
R-PIA. R-PIA caused a transient Ca2+
peak in naive (vehicle-treated) cells (Fig.
4A). Desensitization of the
[Ca2+] response in R-PIA- or
R-PIA/ADA-treated cells occurred rapidly (in minutes) and
was sustained for at least 48 h (Fig. 4B).
R-PIA pretreatment reduced the maximum intracellular calcium
concentration by 2, 30, and 44% at 1, 5, and 15 min, respectively.
This effect was, however, potentiated in the presence of ADA, since the
maximum desensitization (60%) was achieved at 5 min and maintained for up to 48 h (Fig. 4, A and B). No significant
differences in maximum effect were observed when R-PIA
pretreatment was done in the presence or in the absence of ADA (Fig.
4B). It should be noted that ADA pretreatment in the absence
of R-PIA led to a significant and sustained desensitization
(25-45% reduction of the response).

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 4.
Agonist-induced functional desensitization of
A1R in the absence or presence of ADA. A,
cells were loaded with Fura-2/AM (30 min, 25 °C), resuspended in
serum-free DMEM, and preincubated with vehicle (control), 65 nM ADA, 50 nM R-PIA, or 65 nM ADA plus 50 nM R-PIA for 5 min at
37 °C. After extensive washing, intracellular calcium mobilization
was achieved by 50 nM R-PIA as described under
"Experimental Procedures." Traces correspond to a representative
experiment. Panel B, time course of functional
desensitization, measured as R-PIA-induced intracellular
calcium mobilization, after pretreatment of cells with ADA and/or
R-PIA. Intracellular calcium mobilization was achieved as
described in A. For long term desensitization (12, 24, and
48 h), cells were grown in the presence of the reagents prior to
the loading with Fura-2/AM (see "Experimental Procedures"). Data
are presented as percentage of the maximal response obtained for
control cells stimulated with 50 nM R-PIA. Data
are expressed as mean ± S.E. of three separate experiments. *,
p < 0.05; **, p < 0.01; ***,
p < 0.005 with respect to the untreated cells.
|
|
Loss of A1Rs from the Cell
Surface--
Characterization of A1Rs by radioligand
binding using the agonist [3H]R-PIA indicated
the presence of two affinity states of the receptors (Khigh = 0.8-2 nM and
Klow = 10-100 nM) in cell membrane
preparations, whereas only the low affinity state was detected in
intact cells (43). Ligand binding assays were performed in intact cells
preincubated with vehicle (control) or with 50 nM
R-PIA and/or 65 nM ADA. Cells were extensively
washed and assayed for [3H]R-PIA binding at
4 °C. The results indicated a time-dependent loss of
binding sites on the cell membrane of treated cells (Fig. 5). The loss of binding sites after
incubation of cells with ADA in the absence of R-PIA was
small. In contrast, preincubation of cells with 50 nM
R-PIA with or without ADA resulted in a
time-dependent reduction of
[3H]R-PIA binding sites. The presence of ADA
accelerated the reduction of binding sites, from
t1/2 = 10 ± 1 h to
t1/2 = 2.9 ± 0.5 h. The maximum loss of
cell surface binding sites (around 41%) induced by agonist was not
modified by the presence of ADA (Fig. 5).

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 5.
Loss of cell surface
[3H]R-PIA binding sites in response to ADA
and/or R-PIA treatment. Cells were incubated with
vehicle (control), 65 nM ADA ( ), 50 nM
R-PIA ( ), or 65 nM ADA plus 50 nM
R-PIA ( ) for the indicated time at 37 °C. After
pretreatment, cells were washed and incubated for 4 h at 4 °C
with 5 nM [3H]R-PIA. Nonspecific
binding was assessed in the presence of a 400-fold excess of unlabeled
R-PIA. Data (mean ± S.E. of five experiments performed
in quadruplicate) are presented as percentages of the specific binding
with respect to untreated cells. *, p < 0.005; **,
p < 0.001.
|
|
Disappearance of A1Rs from the cell surface of
DDT1MF-2 cells in response to agonist has been described
elsewhere (32). Interestingly, the effect of ADA was evident even when
the protein was prebound to the cell surface and the unbound enzyme was
washed away (Fig. 6). On the other hand,
the disappearance of A1Rs from the cell surface was
reversible. Thus, when chronically stimulated cells were further
cultured for 24 h in the absence of R-PIA, the level of
cell surface expression was recovered. These results indicate that, in
the presence of ADA, R-PIA induces the sequestration of
A1R in intracellular compartments (see below).

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 6.
Internalization of A1Rs in cells
preincubated with ADA. DDT1MF-2 cells were treated
with 65 nM ADA for 2 h at 4 °C. After binding of
ADA to the cell surface, unbound enzyme was washed away, and cells were
treated without (open bar) or with
(striped bar) 50 nM R-PIA
for 24 h at 37 °C. A sample of R-PIA-treated cells
was washed twice in PBS and further cultured for 24 h in absence
of the compound (solid bar). After treatment,
cells were harvested, rinsed in PBS, fixed using 4% paraformaldehyde
in PBS, and prepared for immunostaining using the
fluorescein-conjugated anti-A1R antibody (PC21-FITC, 75 µg/ml). Fluorescence quantification was performed on a EPICS Profile
flow cytometer as indicated under "Experimental Procedures." Data
are presented as percentages with respect to untreated cells. Values
represent the mean ± S.E. from three separate experiments. *,
p < 0.05.
|
|
Internalization of A1Rs Together with ADA--
In
order to determine whether agonist-induced disappearance of binding
sites affects the expression of cell surface ADA (ecto-ADA), fluorocytometry analysis was performed using nonpermeabilized cells.
After pretreatment with medium (control) or 50 nM
R-PIA, cells were fixed, and ecto-ADA was labeled using the
anti-ADA-FITC antibody. A significant time-dependent
decrease in fluorescence intensity was observed after 8 h of
R-PIA treatment, and a maximum decrease (40%) was obtained
at 24 h, which suggests A1R agonist-induced internalization of ecto-ADA (Fig. 7).

View larger version (61K):
[in this window]
[in a new window]
|
Fig. 7.
Cell surface expression of ADA (ecto-ADA) in
response to R-PIA. Cells were untreated (control) or
treated with 50 nM R-PIA for 0-48 h at
37 °C. Cells were then washed once in PBS, fixed using 4%
paraformaldehyde in PBS, and prepared for immunostaining with the
fluorescein-conjugated anti-ADA antibody (ADA-FITC, 75 µg/ml) as
indicated under "Experimental Procedures." Fluorescence intensity
was quantified on an EPICS Profile flow cytometer. Data are presented
as percentages with respect to untreated cells. Values represent the
mean ± S.E. from three separate experiments performed in
triplicate. *, p < 0.05; **, p < 0.01.
|
|
To follow ADA internalization, DDT1MF-2 cells were labeled
with ADA-FITC, which binds to cell surface A1Rs (34). The
labeling was performed in the presence or in the absence of 50 nM R-PIA. After extensive washes in acid buffer,
cells fixed in paraformaldehyde were analyzed by flow cytometry. The
acidic wash was necessary to remove ADA-FITC remaining on the cell
surface; therefore, quantification of intracellular fluorescence is a
direct measure of internalized ADA (see "Experimental Procedures").
A progressive time-dependent incorporation of fluorescence
into the cells, in the period 2-48 h, was observed in the absence of
R-PIA. Maximal incorporation of ADA-FITC, which occurred at
48 h, increased (37%) in the presence of R-PIA. The
differences between control and R-PIA-treated cells were
significant between 8 and 48 h. Internalization of ADA-FITC into
the cells was also analyzed by immunofluorescence and confocal assays.
Cells maintained in the presence of ADA-FITC for 24-72 h showed
accumulations of labeling in intracellular vesicles. R-PIA
treatment for 24-72 h resulted in a marked increase in intracellular labeling in brighter and larger intracellular vesicles (Fig.
8A). These variations were not
due to fluid phase internalization, since R-PIA did not
affect the extent of fluorescein-conjugated bovine serum albumin
internalization (Fig. 8B).

View larger version (51K):
[in this window]
[in a new window]
|
Fig. 8.
Internalization of fluorescein-conjugated ADA
or bovine serum albumin in the absence or presence of
R-PIA. A, cells growing on glass coverslips
in the presence of 65 nM fluorescein-conjugated ADA were
incubated (37 °C) in the absence ( PIA) or presence (+PIA) of 50 nM R-PIA for 24 or 72 h. Glass coverslips
were washed in PBS, fixed, mounted, and analyzed by confocal microscopy
as described under "Experimental Procedures." Panel
B, cells were grown in the presence of 65 nM
fluorescein-conjugated bovine serum albumin in the absence ( PIA) or
presence (+PIA) of 50 nM R-PIA for 72 h.
Cells were processed as indicated in A. Images correspond to
a middle section of representative cells. Scale
bar, 10 µm.
|
|
As shown in Figs. 5 and 9A and
as described elsewhere (32), R-PIA induces the disappearance
of cell surface A1Rs even in the absence of exogenous ADA.
Since cell surface ADA and A1R colocalize, these results
indicate that R-PIA might induce internalization of
A1R together with ADA. We tested this hypothesis by
comparing the distribution of A1Rs and ADA in double
immunofluorescence staining experiments analyzed by confocal
microscopy. Double immunofluorescence staining with the
rhodamine-conjugated rabbit anti-A1R (PC21-TRITC) and
fluorescein-conjugated ADA (ADA-FITC) was performed in control and
R-PIA-treated cells. Incubation of cells with ADA-FITC and PC21-TRITC for 24 h showed staining for ADA and A1R in
intracellular vesicles (Fig. 9B, top).
Superimposition of images revealed a high degree of colocalization
between the two proteins (Fig. 9B, yellow). After
24 h of chronic exposure to 50 nM R-PIA,
perinuclear staining and a marked decrease in the number of
intracellular vesicles containing ADA and A1Rs, accompanied
by a drastic increase in size and brightness, were observed (Fig.
9B, bottom). Colocalization of both proteins
(yellow) was confirmed in numerous cells analyzed at various
planes, indicating that A1Rs and ADA internalize together via the same pathway of endocytosis.

View larger version (57K):
[in this window]
[in a new window]
|
Fig. 9.
Colocalization of internalized ADA and
A1 in the absence or presence of R-PIA.
A, DDT1MF-2 cells were grown in DMEM containing
fluorescein-conjugated anti-A1R antibody (PC21-FITC, 10 µg/ml) in the absence (top) or in the presence
(bottom) of 50 nM R-PIA for 24 h. After treatment, cells were fixed, washed, and analyzed by confocal
microscopy. Images correspond to a middle section of representative
cells. Scale bar, 10 µm. B,
DDT1MF-2 cells were grown in DMEM containing
fluorescein-conjugated ADA (65 nM) and rhodamine-conjugated
anti-A1R antibody (PC21-TRITC, 10 µg/ml) in the absence
(top) or in the presence (bottom) of 50 nM R-PIA for 24 h. After treatment, cells
were fixed, washed, and analyzed by confocal microscopy to detect ADA
(green images) and A1R
(red images). Superimposition of images reveals
the intracellular colocalization of ADA and A1R in
yellow. Scale bar, 10 µm.
|
|
 |
DISCUSSION |
This study provides new insights into ligand-mediated mechanisms
involved in the regulation and trafficking of A1 adenosine receptors. Several studies have demonstrated agonist desensitization by
means of a reduced inhibition of adenylate cyclase associated with a
net loss of binding sites and Gi proteins (29, 30, 31).
However, little was known about the biochemical mechanisms involved in
desensitization and down-regulation or the intracellular pathways
involved in the trafficking of A1Rs. Another interesting question concerns the role of ecto-ADA in the desensitization of
A1R due to the fact that A1R and ADA interact
on the cell surface (34). The high expression (100,000 receptors/cell)
of A1Rs (43), capable of interacting with ADA (34) makes
DDT1MF-2 cells a suitable model to study the role of ADA in
the regulation of A1R expression.
By means of immunofluorescence staining using antibodies against
A1R and ADA, a nearly homogenous distribution of
A1R and ADA over the plasma membrane of
DDT1MF-2 cells was observed. Confocal analysis demonstrated
a high degree of colocalization between ADA and A1R, which
was maintained in the cell surface clusters formed after
R-PIA treatment. The appearance of clusters was accelerated when cells were incubated simultaneously with R-PIA and ADA.
This suggests an ADA-mediated regulation of ligand-induced
redistribution of A1Rs. Prolonged agonist stimulation
induced the disappearance of membrane A1R binding sites on
DDT1MF-2 cell surface, as previously shown (29). This
phenomenon was also accelerated in the presence of ADA, although the
maximum effect was the same as that achieved by R-PIA
alone.
Ecto-ADA also underwent R-PIA-induced internalization.
Internalized ADA appeared in relatively small intracellular vesicles, where it colocalized with A1R. This may be an
agonist-independent process representing the natural recycling of the
ectoenzyme, or it may be due to the presence of endogenous adenosine.
This latter possibility seems unlikely, since no internalization of A1R occurred in the absence of R-PIA. Although
ADA internalization may be agonist-independent, long term agonist
treatment increased the degree of ADA internalization. Double
immunofluorescence assays analyzed by confocal microscopy showed
colocalization of ADA and A1Rs in the same intracellular
vesicles. All these findings suggest that ADA and A1Rs
participate in the regulation of each other and that this mutual
regulation includes internalization via the same endocytic pathway. To
our knowledge, this is the first report describing the trafficking of a
purine ectoenzyme and demonstrating a common internalization pathway
for A1R and the ectoprotein (ecto-ADA) interacting with
it.
During the agonist-mediated redistribution (clustering) of
A1Rs on the cell surface, a time-dependent
phosphorylation of A1Rs occurs. Basal A1R
phosphorylation increased rapidly between 5 and 15 min as a consequence
of agonist stimulation. Agonist-induced A1R phosphorylation
was accelerated and enhanced in the presence of exogenous ADA. Taking
into account these data and the fact that ADA increased ligand-induced
A1R aggregation, the involvement of phosphorylation in the
clustering of A1 receptors is highly probable. In fact,
clustering and internalization of A1Rs were mimicked by
activators of protein kinase A and protein kinase C (32), thus showing
the need for Ser/Thr phosphorylation in these events. Simultaneous to
ligand-induced receptor phosphorylation and aggregation, a decrease in
ligand-induced second messenger response, i.e. a functional
desensitization, was observed. Functional desensitization was a rapid
time-dependent process that occurred within minutes but
remained for hours. This contrasts with data found in Chinese hamster
ovary cells transfected with the human A1R. Overexpressed
A1Rs were neither phosphorylated nor desensitized after 10 min of R-PIA treatment. Interestingly, a stably expressed chimeric A1-A3 adenosine receptor, in which the
C-terminal domain of A1R distal to its predicted
palmitoylation site was replaced by the corresponding region of the
A3 subtype, was able to undergo functional desensitization
and agonist-stimulated phosphorylation (44). Differences in amino acid
sequence of the C-terminal domain of A1R and
A3R can account for the distinct desensitization pathways found in Chinese hamster ovary cells. However, the short term desensitization and phosphorylation reported here for A1R
in DDT1MF-2 cells demonstrate that the cellular environment
near the plasma membrane is important for receptor regulation. The
regulation of A1R phosphorylation and desensitization by
cell surface ADA is an example of the relevance of the membrane
components for receptor regulation. To our knowledge, this is a novel
finding, since no other receptor whose function is modulated by an
ectoenzyme has been described.
Rapid ligand-induced desensitization of G protein-coupled receptors
such as 2-ARs (45), angiotensin II receptor (46), cholecystokinin receptor (47), -opioid receptor (48), and neurokinin
1 receptor (49) correlates with receptor phosphorylation and uncoupling
from G proteins. Several reports have provided evidence that receptor
desensitization is short term and does not require endocytosis (45, 50,
51). An exception is the agonist-induced desensitization of the
secretin receptor, which occurs in the absence of receptor
phosphorylation and is basically induced by receptor internalization
(52). 2-AR (22, 23) and neurokinin 1 receptor (49)
resensitization seems to be a consequence of receptor dephosphorylation
in endosomes and their recycling back to the plasma membrane. Our data
indicate that although receptor phosphorylation returns to basal level,
desensitization of A1R continued for hours (see Figs. 3 and
4). In a recent study, desensitization of the cholecystokinin receptor
occurred in both rat pancreatic acinar cells and transfected Chinese
hamster ovary cells, although receptor dephosphorylation was evident
only in acinar cells. Moreover, cholecystokinin receptor in Chinese
hamster ovary cells maintained its phosphorylation state throughout the time of internalization, whereas the acinar cell receptor was dephosphorylated to its basal state while remaining on the cell surface
(47). All of these data suggest differences in regulation of G
protein-coupled receptors, depending on the receptor subtype and the
cell system in which the receptor is expressed.
The results provide new insights into the regulation and trafficking of
A1Rs in response to agonist stimulation. Moreover, it is
shown that ecto-ADA, besides its role in regulating the extracellular
concentration of adenosine, modulates all the regulatory mechanisms
involved in desensitization of A1R. It is remarkable that
ADA and A1R colocalize on the cell surface and in
intracellular vesicles after internalization. During the
agonist-dependent internalization process, ADA and
A1R follow a common endocytic pathway. This is probably the
molecular mechanism underlying the recent discovery of increased plasma
adenosine levels found after caffeine or sulfophenylteophylline consumption (53). Although it does not occur in DDT1MF-2
cells, there are cell types whose A1Rs internalize in
response to xanthine antagonists.2 The probable
internalization of ADA and A1R from the cell surface in
those antagonist-treated cells would lead to a decrease in adenosine
deamination and, subsequently, to an increase in the extracellular
levels of the nucleoside. As pointed out by Conlay et al.
(53), alteration of adenosine levels by sudden changes in
methylxanthine consumption could affect the physiology of many organ
systems and provoke bronchospasm, alter blood pressure, change cardiac
rhythms, or influence seizure thresholds. Confirmation that
internalization of ecto-ADA is the cause of these alterations would be
very valuable from a physiological and therapeutic point of view.
 |
ACKNOWLEDGEMENTS |
We thank Catalina Relaño (Servei de
Cultius Cel.lulars) and Susana Castel and Jaume Comas (Serveis
Científico-Tècnics) for excellent technical assistance
and Robin Rycroft (Servei d'Assesorament Lingüístic) for
assistance in the preparation of this manuscript. We are grateful for
the advice received from Dr. Ampar Castell from Biokit Company
(Llicà d'Amunt, Barcelona), which facilitated production of
anti-ADA and anti-A1R antibodies.
 |
FOOTNOTES |
*
This work was supported by a joint (Echevarne Fundation and
Spanish Ministry of Education) PETRI Grant (PTR92/0047) administered by
Fundació Bosch i Gimpera and by Fondo de Investigaciones
Sanitarias de la Seguridad Social Grant 91/0272, Comissió
Interdepartamental de Recerca i Innovació
Tecnológica-Comisión Interministerial de Ciencia y
Tecnología, Spain (CICYT) Grant QFN93/4423, and CICYT Grants
PB94/0941 and SAF97/0066.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept.
Bioquímica i Biologia Molecular, Universitat de Barcelona,
Facultat de Química, Martí i Franquès 1, 08028 Barcelona, Spain. Tel.: 34-934021208; Fax: 34-934021219; E-mail:
r.franco{at}sun.bq.ub.es.
1
The abbreviations used are: A1R,
A1 adenosine receptor; ADA, adenosine deaminase;
R-PIA,
N6-(R)-(phenylisopropyl)adenosine;
FITC, fluorescein isothiocyanate; TRITC, rhodamine isothiocyanate;
2-AR, 2-adrenergic receptor; DMEM,
Dulbecco's modified Eagle's medium; PBS, phosphate-buffered saline;
HBSS, Hanks' balanced salt solution.
2
A. Navarro, C. A. Saura, J. Mallol, E. I. Canela, C. Lluis, and R. Franco, manuscript in preparation.
 |
REFERENCES |
-
Palmer, T. M.,
and Stiles, G. L.
(1995)
Neuropharmacol.
34,
683-694[CrossRef][Medline]
[Order article via Infotrieve]
-
Fredholm, B. B.,
and Dunwiddie, T. V.
(1988)
Trends Pharmacol. Sci.
9,
130-134[CrossRef][Medline]
[Order article via Infotrieve]
-
Fredholm, B. B.
(1995)
Pharmacol. Toxicol.
76,
228-239[Medline]
[Order article via Infotrieve]
-
Belardinelli, L.
(1993)
Drug Develop. Res.
28,
263-267[CrossRef]
-
Spielman, W. S.,
and Arend, L. J.
(1991)
Hypertension
17,
117-130[Abstract/Free Full Text]
-
Elhashim, A.,
Dagostino, B.,
Matera, M. G.,
and Page, C.
(1996)
Br. J. Pharmacol.
119,
1262-1268[Medline]
[Order article via Infotrieve]
-
Nyce, J. W.,
and Metzger, W. J.
(1997)
Nature
385,
721-725[CrossRef][Medline]
[Order article via Infotrieve]
-
Munshi, R.,
Pang, I.-H.,
Sternweis, P. C.,
and Linden, J.
(1991)
J. Biol. Chem.
266,
22285-22289[Abstract/Free Full Text]
-
Jockers, R.,
Linder, M. E.,
Hohenegger, M.,
Nanoff, C.,
Bertin, B.,
Strosberg, A. D.,
Marullo, S.,
and Freissmuth, M.
(1994)
J. Biol. Chem.
269,
32077-32084[Abstract/Free Full Text]
-
Figler, R. A.,
Graber, S. G.,
Lindorfer, M. A.,
Yasuda, H.,
Linden, J.,
and Garrison, J. C.
(1996)
Mol. Pharmacol.
50,
1587-1595[Abstract]
-
Londos, C.,
Cooper, D. M. F.,
and Wolff, T.
(1980)
Proc. Natl. Acad. Sci. U. S. A.
77,
2551-2554[Abstract/Free Full Text]
-
Lohse, M. J.,
Lenschow, V.,
and Swabe, U.
(1984)
Mol. Pharmacol.
26,
1-9[Abstract]
-
Casadó, V.,
Canti, C.,
Mallol, J.,
Canela, E. I.,
Lluís, C.,
and Franco, R.
(1990)
J. Neurosci. Res.
26,
461-473[CrossRef][Medline]
[Order article via Infotrieve]
-
Franco, R.,
Casadó, V.,
Ciruela, F.,
Mallol, J.,
Lluis, C.,
and Canela, E. I.
(1996)
Biochemistry.
35,
3007-3015[CrossRef][Medline]
[Order article via Infotrieve]
-
Casadó, V.,
Mallol, J.,
Canela, E. I.,
Lluís, C.,
and Franco, R.
(1991)
FEBS Lett.
286,
221-224[CrossRef][Medline]
[Order article via Infotrieve]
-
Premont, R. T.,
Inglese, J.,
and Lefkowitz, R. J.
(1995)
FASEB J.
9,
175-182[Abstract]
-
Post, S. R.,
Aguila-Buhain, O.,
and Insel, P. A.
(1996)
J. Biol. Chem.
271,
895-900[Abstract/Free Full Text]
-
Lohse, M. J.,
Benovic, J. L.,
Codina, J.,
Caron, M. G.,
and Lefkowitz, R. J.
(1990)
Science
248,
1547-1550[Abstract/Free Full Text]
-
Attramadal, H.,
Arriza, J. L.,
Aoki, C.,
Dawson, T. M.,
Codina, J.,
Kwatra, M. M.,
Snyder, S. H.,
Caron, M. G.,
and Lefkowitz, R. J.
(1992)
J. Biol. Chem.
267,
17882-17890[Abstract/Free Full Text]
-
Fergusson, S. S. G.,
Downey, W. E., III,
Colapietro, A.-M.,
Barak, L. S.,
Ménard, L.,
and Caron, M. G.
(1996)
Science
271,
363-366[Abstract]
-
Goodman, O. B.,
Krupnick, J. G.,
Santini, F.,
Gurevich, V. V.,
Penn, R. B.,
Gagnon, A. W.,
Keen, J. H.,
and Benovic, J. L.
(1996)
Nature
383,
447-450[CrossRef][Medline]
[Order article via Infotrieve]
-
Pippig, S.,
Andexinger, S.,
and Lohse, M. J.
(1995)
Mol. Pharmacol.
47,
666-676[Abstract]
-
Krueger, K. M.,
Daaka, Y.,
Pitcher, J. A.,
and Lefkowitz, R. J.
(1997)
J. Biol. Chem.
272,
5-8[Abstract/Free Full Text]
-
Dennis, D. M.,
Shryock, J. C.,
and Belardinelli, L.
(1995)
J. Pharmacol. Exp. Ther.
272,
1024-1035[Abstract/Free Full Text]
-
Longabaugh, J. P.,
Didsbury, J.,
Spiegel, A.,
and Stiles, G. L.
(1989)
Mol. Pharmacol.
36,
681-688[Abstract]
-
Lee, H. T.,
Thompson, C. I.,
Hernandez, A.,
Lewy, J. L.,
and Belloni, F. L.
(1993)
Am. J. Physiol.
265,
H1916-H1927[Abstract/Free Full Text]
-
Fernández, M.,
Svenningsson, P.,
and Fredholm, B. B.
(1996)
Life Sci.
9,
769-776
-
Ruiz, A.,
Sanz, J. M.,
Gonzalez-Calero, G.,
Fernández, M.,
Andrés, A.,
Cubero, A.,
and Ros, M.
(1996)
Biochim. Biophys. Acta.
1310,
168-174[Medline]
[Order article via Infotrieve]
-
Ramkumar, V.,
Olah, M. E.,
Jacobson, K. A.,
and Stiles, G. L.
(1991)
Mol. Pharmacol.
40,
639-647[Abstract]
-
Green, A.,
Johnson, J. L.,
and Milligan, G.
(1990)
J. Biol. Chem.
265,
5206-5210[Abstract/Free Full Text]
-
Green, A.,
Milligan, G.,
and Dobias, S. B.
(1992)
J. Biol. Chem.
267,
3223-3229[Abstract/Free Full Text]
-
Ciruela, F.,
Saura, C,
Canela, E. I.,
Mallol, J.,
Lluis, C.,
and Franco, R.
(1997)
Mol. Pharmacol.
52,
788-797[Abstract/Free Full Text]
-
Franco, R.,
Casadó, V.,
Ciruela, F.,
Saura, C.,
Mallol, J.,
Canela, E. I.,
and Lluis, C.
(1997)
Prog. Neurobiol.
52,
283-294[CrossRef][Medline]
[Order article via Infotrieve]
-
Ciruela, F.,
Saura, C.,
Canela, E. I.,
Mallol, J.,
Lluis, C.,
and Franco, R.
(1996)
FEBS Lett.
380,
219-223[CrossRef][Medline]
[Order article via Infotrieve]
-
Saura, C.,
Ciruela, F.,
Casadó, V.,
Canela, E. I.,
Mallol, J.,
Lluis, C.,
and Franco, R.
(1996)
J. Neurochem.
66,
675-682
-
Aran, J. M.,
Colomer, D.,
Matutes, E.,
Vives-Corrons, J. L.,
and Franco, R.
(1991)
J. Histochem. Cytochem.
39,
1001-1007[Abstract]
-
Ciruela, F.,
Casadó, V.,
Mallol, J.,
Canela, E. I.,
Lluis, C.,
and Franco, R.
(1995)
J. Neurosci. Res.
42,
818-829[CrossRef][Medline]
[Order article via Infotrieve]
-
Sorensen, K.,
and Brodbeck, U.
(1986)
Experentia
42,
161-162[CrossRef]
-
Yang E-B,
Wang, D-F.,
Mack, P.,
and Cheng, L-Y.
(1996)
Biochem. Biophys. Res. Commun.
224,
309-317[CrossRef][Medline]
[Order article via Infotrieve]
-
Grynkiewicz, G.,
Poenie, M.,
and Tsien, R. Y.
(1985)
J. Biol. Chem.
260,
3440-3450[Abstract/Free Full Text]
-
Gerwins, P.,
and Fredholm, B. B.
(1992)
J. Biol. Chem.
267,
16081-16087[Abstract/Free Full Text]
-
Dickenson, J. M.,
and Hill, S. J.
(1993)
Br. J. Pharmacol.
108,
85-92[Medline]
[Order article via Infotrieve]
-
Gerwins, P.,
Nordstedt, C.,
and Fredholm, B. B.
(1990)
Mol. Pharmacol.
38,
660-666[Abstract]
-
Palmer, T. M.,
Benovic, J. L.,
and Stiles, G. L.
(1996)
J. Biol. Chem.
271,
15272-15278[Abstract/Free Full Text]
-
Lohse, M. J.,
Benovic, J. L.,
Caron, M. G.,
and Lefkowitz, R. J.
(1990)
J. Biol. Chem.
265,
3202-3209[Abstract/Free Full Text]
-
Oppermann, M.,
Freedman, N. J.,
Alexander, R. W.,
and Lefkowitz, R. J.
(1996)
J. Biol. Chem.
271,
13266-13272[Abstract/Free Full Text]
-
Rao, R. V.,
Roettger, B. F.,
Hadac, E. M.,
and Miller, L. J.
(1997)
Mol. Pharmacol.
51,
185-192[Abstract/Free Full Text]
-
Pei, G.,
Kieffer, B. L.,
Lefkowitz, R. J.,
and Freedman, N. J.
(1995)
Mol. Pharmacol.
48,
173-177[Abstract]
-
Garland, A. M.,
Grady, E. F.,
Lovett, M.,
Vigna, S. R.,
Frucht, M. M.,
Krause, J. E.,
and Bunnett, N. W.
(1996)
Mol. Pharmacol.
49,
438-446[Abstract]
-
Yu, S. S.,
Lefkowitz, R. J.,
and Hausdorff, W. P.
(1993)
J. Biol. Chem.
268,
337-341[Abstract/Free Full Text]
-
Sanders, M. A.,
and LeVine, H., III
(1996)
J. Neurochem.
67,
2362-2372[Medline]
[Order article via Infotrieve]
-
Holtmann, M. H.,
Roettger, B. F.,
Pinon, D. I.,
and Miller, L. J.
(1996)
J. Biol. Chem.
271,
23566-23571[Abstract/Free Full Text]
-
Conlay, L. A.,
Conant, J. A.,
deBros, F.,
and Wurtman, R.
(1997)
Nature
389,
136[CrossRef][Medline]
[Order article via Infotrieve]
Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
P. Saccucci, C. Arpino, R. Rizzo, A. Gagliano, A. Volzone, C. Lalli, C. Galasso, and P. Curatolo
Association of Adenosine Deaminase Polymorphism With Mild Mental Retardation
J Child Neurol,
September 1, 2006;
21(9):
753 - 756.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
H. K. Eltzschig, M. Faigle, S. Knapp, J. Karhausen, J. Ibla, P. Rosenberger, K. C. Odegard, P. C. Laussen, L. F. Thompson, and S. P. Colgan
Endothelial catabolism of extracellular adenosine during hypoxia: the role of surface adenosine deaminase and CD26
Blood,
September 1, 2006;
108(5):
1602 - 1610.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. P. Walsh and J. M. Marshall
The role of adenosine in the early respiratory and cardiovascular changes evoked by chronic hypoxia in the rat
J. Physiol.,
August 15, 2006;
575(1):
277 - 289.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Willems, M. E. Reichelt, J. G. Molina, C.-X. Sun, J. L. Chunn, K. J. Ashton, J. Schnermann, M. R. Blackburn, and J. P. Headrick
Effects of adenosine deaminase and A1 receptor deficiency in normoxic and ischaemic mouse hearts
Cardiovasc Res,
July 1, 2006;
71(1):
79 - 87.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Zhang, D. M. Conrad, J. J. Butler, C. Zhao, J. Blay, and D. W. Hoskin
Adenosine Acts through A2 Receptors to Inhibit IL-2-Induced Tyrosine Phosphorylation of STAT5 in T Lymphocytes: Role of Cyclic Adenosine 3',5'-Monophosphate and Phosphatases
J. Immunol.,
July 15, 2004;
173(2):
932 - 944.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Y. Tan, M. Mujoomdar, and J. Blay
Adenosine Down-Regulates the Surface Expression of Dipeptidyl Peptidase IV on HT-29 Human Colorectal Carcinoma Cells: Implications for Cancer Cell Behavior
Am. J. Pathol.,
July 1, 2004;
165(1):
319 - 330.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. J Ray, M. R Abbas, A. M Coney, and J. M Marshall
Interactions of adenosine, prostaglandins and nitric oxide in hypoxia-induced vasodilatation: in vivo and in vitro studies
J. Physiol.,
October 1, 2002;
544(1):
195 - 209.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Hillion, M. Canals, M. Torvinen, V. Casado, R. Scott, A. Terasmaa, A. Hansson, S. Watson, M. E. Olah, J. Mallol, et al.
Coaggregation, Cointernalization, and Codesensitization of Adenosine A2A Receptors and Dopamine D2 Receptors
J. Biol. Chem.,
May 10, 2002;
277(20):
18091 - 18097.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. B. Fredholm, A. P. IJzerman, K. A. Jacobson, K.-N. Klotz, and J. Linden
International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors
Pharmacol. Rev.,
December 1, 2001;
53(4):
527 - 552.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. A. Deuchars, R. E. Brooke, and J. Deuchars
Adenosine A1 Receptors Reduce Release from Excitatory But Not Inhibitory Synaptic Inputs onto Lateral Horn Neurons
J. Neurosci.,
August 15, 2001;
21(16):
6308 - 6320.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Ginés, F. Ciruela, J. Burgueño, V. Casadó, Enric. I. Canela, J. Mallol, C. Lluís, and R. Franco
Involvement of Caveolin in Ligand-Induced Recruitment and Internalization of A1 Adenosine Receptor and Adenosine Deaminase in an Epithelial Cell Line
Mol. Pharmacol.,
April 16, 2001;
59(5):
1314 - 1323.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
S. Sarrió, V. Casadó, M. Escriche, F. Ciruela, J. Mallol, E. I. Canela, C. Lluis, and R. Franco
The Heat Shock Cognate Protein hsc73 Assembles with A1 Adenosine Receptors To Form Functional Modules in the Cell Membrane
Mol. Cell. Biol.,
July 15, 2000;
20(14):
5164 - 5174.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
S. Ginés, J. Hillion, M. Torvinen, S. Le Crom, V. Casadó, E. I. Canela, S. Rondin, J. Y. Lew, S. Watson, M. Zoli, et al.
Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes
PNAS,
July 5, 2000;
(2000)
150241097.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
B. T. Andresen, D. G. Gillespie, Z. Mi, R. K. Dubey, and E. K. Jackson
Role of Adenosine A1 Receptors in Modulating Extracellular Adenosine Levels
J. Pharmacol. Exp. Ther.,
October 1, 1999;
291(1):
76 - 80.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
M Mirabet, C Herrera, O. Cordero, J Mallol, C Lluis, and R Franco
Expression of A2B adenosine receptors in human lymphocytes: their role in T cell activation
J. Cell Sci.,
January 2, 1999;
112(4):
491 - 502.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Herrera, C. Morimoto, J. Blanco, J. Mallol, F. Arenzana, C. Lluis, and R. Franco
Comodulation of CXCR4 and CD26 in Human Lymphocytes
J. Biol. Chem.,
May 25, 2001;
276(22):
19532 - 19539.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Gines, J. Hillion, M. Torvinen, S. Le Crom, V. Casado, E. I. Canela, S. Rondin, J. Y. Lew, S. Watson, M. Zoli, et al.
Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes
PNAS,
July 18, 2000;
97(15):
8606 - 8611.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1998 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|